Anthraquinone

Anthraquinone

SCHEMBL7205968

N.O=C1c2ccccc2C(=O)c2ccccc21

nearest known ligand 0.92

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.92
KMT2A Q03164 3/20 0.92
CDC25B P30305 3/20 0.92
MAOA P21397 5/20 0.73
RAB9A P51151 4/20 0.73
APAF1 O14727 3/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
POLB P06746 3/20 0.73
MAPT P10636 3/20 0.73
TDP2 O95551 2/20 0.73
KDM4E B2RXH2 2/20 0.73
LMNA P02545 2/20 0.73
S100A4 P26447 2/20 0.73
BLM P54132 2/20 0.73
NPC1 O15118 2/20 0.73
MAPK1 P28482 2/20 0.73
CES2 O00748 1/20 0.73
TERT O14746 1/20 0.73
PLIN1 O60240 1/20 0.73
S1PR4 O95977 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anthraquinone SCHEMBL6305988 1.00 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A
Ammonia Solution, Strong SCHEMBL27853162 0.96 MEN1 (0.86) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL14943 0.96 MEN1 (1.00) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL1901249 0.96 MEN1 (1.00) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL29358690 0.96 MEN1 (1.00) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL21834979 0.93 MEN1 (0.80) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL6415478 0.92 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL11300863 0.92 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL10991985 0.92 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A
Anthraquinone SCHEMBL8081485 0.92 MEN1 (0.92) MEN1KMT2ACDC25BMAOARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115418217-B Organic red long afterglow material and preparation method and application thereof 承德石油高等专科学校 2024-06-14 CN claimed
CN-115418217-A Organic red long-afterglow material and preparation method and application thereof 承德石油高等专科学校 2022-12-02 CN claimed
CN-110552214-A Preparation method of long-acting antibacterial fabric, product and application thereof TONGXI GROUP CO LTD 2019-12-10 CN claimed
CN-115418217-B Organic red long afterglow material and preparation method and application thereof 承德石油高等专科学校 2024-06-14 CN disclosed
CN-115418217-B Organic red long afterglow material and preparation method and application thereof 承德石油高等专科学校 2024-06-14 CN disclosed
US-20230279011-A1 WATER-SOLUBLE TRYPTHANTRIN DERIVATIVES FOR REDOX FLOW BATTERIES UNIVERSIDADE DE COIMBRA (PT) 2023-09-07 US disclosed
EP-4211137-A1 WATER-SOLUBLE TRYPTHANTRIN DERIVATIVES FOR REDOX FLOW BATTERIES Universidade de Coimbra (PT) 2023-07-19 EP disclosed
WO-2023097995-A1 APPLICATION OF COMPOUND IN SOLAR CELL 西安隆基乐叶光伏科技有限公司 2023-06-08 WO disclosed
US-20230067047-A1 LIGHT AND MOISTURE CURABLE COMPOSITIONS 3M INNOVATIVE PROPERTIES COMPANY 2023-03-02 US disclosed
CN-114196973-B Method for electrochemically synthesizing aza-anthraquinone derivative 南京工业大学 2022-12-09 CN disclosed
CN-115418217-A Organic red long-afterglow material and preparation method and application thereof 承德石油高等专科学校 2022-12-02 CN disclosed
CN-104479394-A Method for continuously preparing azo pigment in branch spiral tube SUZHOU SUNMUN TECHNOLOGY CO LTD 2015-04-01 CN disclosed
US-20030114362-A1 Penta-or tetrapeptide binding to somatostatin receptors and the use of the same NOVASPIN BIOTECH GMBH (DE) 2003-06-19 US disclosed
WO-2002100885-A2 A PENTA- OR TETRAPEPTIDE BINDING TO SOMATOSTATIN RECEPTORS AND THE USE OF THE SAME NOVASPIN BIOTECH GMBH (DE) 2002-12-19 WO disclosed
EP-0820483-B1 METHOD OF PHOTOCHEMICAL IMMOBILIZATION OF LIGANDS USING QUINONES JAKOBSEN MOGENS HAVSTEEN (DK) 2000-12-13 EP disclosed
US-6033784-A Method of photochemical immobilization of ligands using quinones JAKOBSEN MOGENS HAVSTEEN (DK) 2000-03-07 US disclosed
EP-0820483-A1 METHOD OF PHOTOCHEMICAL IMMOBILIZATION OF LIGANDS USING QUINONES Jakobsen, Mogens Havsteen (DK) 1998-01-28 EP disclosed
WO-1996031557-A1 METHOD OF PHOTOCHEMICAL IMMOBILIZATION OF LIGANDS USING QUINONES JACOBSEN MOGENS HAVSTEEN (DK) 1996-10-10 WO disclosed
US-3983171-A Anionic surface active compositions L'OREAL (FR) 1976-09-28 US disclosed
US-3959460-A Cosmetic compositions containing anionic surface active agent containing mono- or polyhydroxylated mono- or poly ether chains and a terminal acid group L'OREAL (FR) 1976-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279011-A1 WATER-SOLUBLE TRYPTHANTRIN DERIVATIVES FOR REDOX FLOW BATTERIES TPSG1, TPSB2, MAOB MEN1 626/4885KMT2A 2547/4885CDC25B 58/4885
US-20030114362-A1 Penta-or tetrapeptide binding to somatostatin receptors and the use of the same SSTR5, SSTR3, SCTR MEN1 629/4885KMT2A 4510/4885CDC25B 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.